69
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Prevalence and time course of hepatitis B virus infection in patients with systemic lupus erythematosus under immunosuppressive therapy

, , , , , & show all
Pages 1094-1100 | Received 25 Jun 2012, Accepted 31 Oct 2012, Published online: 14 Jan 2014

References

  • Lee WM, Hepatitis B. Virus infection. N Engl J Med. 1997; 337:1733–1745.
  • Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, Chien RN, et al. Chronic hepatitis B virus infection in Asian countries. J Gastroenterol Hepatol. 2000; 15:1356–1361.
  • Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med. 2004; 350:1118–1129.
  • Umemura T, Tanaka E, Kiyosawa K, Kumada H. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis. 2008; 47:e52–e56.
  • Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011; 21:16–23.
  • Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum. 1997; 40:1725
  • Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005; 353:2550–2558.
  • Kim YJ, Bae SC, Sung YK, Kim TH, Jun JB, Yoo DH, et al. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-α blocker in the treatment of rhematic diseases. J Rheumatol. 2010; 37:346–350.
  • Minuk GY, Sun DF, Greenberg R, Zhang M, Hawkins K, Uhanova J, et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology. 2004; 40:1072–1077.
  • Demir M, Serin E, Gokturk S, Ozturk NA, Kulaksizoglu S, Yulmaz U. The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients. Eur J Gastroenterol Hepatol. 2008; 20:668–673.
  • Yuen MF, Lee CK, Wong DK, Fung J, Hung I, Hsu A, et al. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut. 2010; 10:1389–1393.
  • Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology. 2003; 37:1172–1179.
  • Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011; 21:621–627.
  • Chng HH, Fock KM, Chew CN, Guan R, Feng PH, Boey ML, et al. Hepatitis B virus infection in patients with systemic lupus erythematosus. Singapore Med J. 1993; 34:325–326.
  • Lu CL, Tsai ST, Chan CY, Hwang SJ, Tsai CY, Wu JC, et al. Hepatitis B infection and changes in interferon-alpha and -gamma production in patients with systemic lupus erythematosus in Taiwan. J Gastroenterol Hepatol. 1997; 12:272–276.
  • Abu-Shakra M, EI-Sana S, Margalith M, Sikuler E, Neumann L, Buskila D. Hepatitis B and C viruses serology in patients with SLE. Lupus.. 1997; 6:543–544.
  • Bonafede RP, Staden M, Klemp P. Hepatitis B virus infection and liver function in patients with systemic lupus erythematosus. J Rheumatol. 1986; 13:1050–1052.
  • Permin H, Aldershvile J, Nielsen J. Hepatitis B virus infection in patients with rheumatic diseases. Ann Rheum Dis. 1982; 41:479–482.
  • Ram M, Anaya JM, Barzilai O, Izhaky D, Katz BP, Blank M, et al. The putative protective role of hepatitis B virus (HBV) infection from autoimmune disorders. Autoimmun Rev. 2008; 7:621–625.
  • Charpin C, Guis S, Colson P, Borentain P, Mattei JP, Alcaraz P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthr Res Ther.. 2009; 11:R179
  • Tanaka E, Urata Y. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-α inhibitors. Hepatol Res.. 2012; 42:333–339.
  • Wands JR, Chuna CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975; 68:105–112.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.